Gordon Sonya G, Saunders Ashley B, Roland Risa M, Winter Randolph L, Drourr Lori, Achen Sarah E, Hariu Crystal D, Fries Ryan C, Boggess May M, Miller Matthew W
Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, College of Science, Texas A&M University, College Station, TX 77843, USA.
J Am Vet Med Assoc. 2012 Jul 1;241(1):89-94. doi: 10.2460/javma.241.1.89.
To determine the effect of PO administration of pimobendan on clinical and echocardiographic variables and survival time in cats with heart failure characterized by ventricular systolic dysfunction.
Retrospective cohort study.
27 client-owned cats (16 male and 11 female) with heart failure, treated with pimobendan (mean ± SD dosage, 0.26 ± 0.08 mg/kg [0.118 ± 0.036 mg/lb], PO, q 12 h).
Information on medical history, laboratory results, diagnostic imaging findings, treatments received, and survival time were obtained from medical records of cats that received pimobendan because of cardiac disease. When possible, additional follow-up information was obtained through telephone interviews with referring veterinarians and owners.
The mean ± SD age of all 27 cats was 8.9 ± 5.2 years. All cats had received several cardiac medications. Types of heart disease represented included unclassified cardiomyopathy (CM; n = 11 [41%]), dilated CM (8 [30%]), arrhythmogenic right ventricular CM (4 [15%]), congenital heart disease (3 [11 %]), and hypertrophic CM with regional hypokinesis (1 [4%]). All cats had ventricular systolic dysfunction. One cat with systolic anterior motion of the mitral valve became severely hypotensive after initial administration of pimobendan and was excluded from the survival analysis. Median survival time was 167 days (95% confidence interval, 32 to 339 days).
Pimobendan appeared to be well tolerated in cats with heart failure characterized by ventricular systolic dysfunction of various etiologies. Cats with systolic anterior motion of the mitral valve may develop systemic hypotension when treated with pimobendan. Additional studies are needed to establish dosages for pimobendan and its effects before it can be recommended for treatment of cats with CHF.
确定口服匹莫苯丹对以心室收缩功能障碍为特征的猫心力衰竭的临床、超声心动图变量及生存时间的影响。
回顾性队列研究。
27只客户拥有的心力衰竭猫（16只雄性和11只雌性），接受匹莫苯丹治疗（平均±标准差剂量，0.26±0.08mg/kg[0.118±0.036mg/lb]，口服，每12小时一次）。
从因心脏病接受匹莫苯丹治疗的猫的病历中获取病史、实验室检查结果、诊断性影像学检查结果、接受的治疗及生存时间等信息。如有可能，通过与转诊兽医和猫主人的电话访谈获取额外的随访信息。
27只猫的平均±标准差年龄为8.9±5.2岁。所有猫都接受过几种心脏药物治疗。所代表的心脏病类型包括未分类的心肌病（CM；n=11[41%]）、扩张型CM（8[30%]）、致心律失常性右心室CM（4[15%]）、先天性心脏病（3[11%]）和伴有局部运动减弱的肥厚型CM（1[4%]）。所有猫都存在心室收缩功能障碍。1只患有二尖瓣收缩期前向运动的猫在首次服用匹莫苯丹后出现严重低血压，被排除在生存分析之外。中位生存时间为167天（95%置信区间，32至339天）。
匹莫苯丹似乎在各种病因导致心室收缩功能障碍的心力衰竭猫中耐受性良好。患有二尖瓣收缩期前向运动的猫在接受匹莫苯丹治疗时可能会出现全身性低血压。在推荐将其用于治疗猫慢性心力衰竭之前，需要进行更多研究以确定匹莫苯丹的剂量及其效果。
